Treatment of hidradenitis suppurativa with tumour necrosis factor-α inhibitors

Acta Dermato-Venereologica

Volumn 89, Issue 6, 2009, Pages 595-600

  Haslund, Pia ^a   Lee, Robert A ^b   Jemec, Gregor B E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Etanercept: adalimumab; Hidradenitis suppurativa; Infliximab; Tumour necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE;

ABSENCE OF SIDE EFFECTS; ACNE; CANDIDIASIS; CHORIORETINITIS; CROHN DISEASE; DATA BASE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MONOTHERAPY; PNEUMOCOCCAL SEPSIS; PRIORITY JOURNAL; PSORIASIS; PUBLICATION; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SUPPURATIVE HIDRADENITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71949106893     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0747     Document Type: Review

References (62)

1. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56: 451-461.
2. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194. (Pubitemid 26260243)
3. Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis 1993; 8: 117-119. (Pubitemid 23285294)
4. Burrows NP, Jones RR. Crohn's disease in association with hidradenitis suppurativa. Br J Dermatol 1992; 126: 523.
5. Wismann MC. Hidradenitis suppurativa: a review. Dermatol Ther 2004; 17: 50-54.
6. Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198: 261-264. (Pubitemid 29281414)
7. Von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813.
8. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623.
9. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 2004; 5: 1767-1770.
10. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int Dermatol 1983; 22: 325-328.
11. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Dermatol 1998; 39: 971-974. (Pubitemid 28547731)
12. Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115: 263-268.
13. Vahlquist A, Griffiths WAD. Retinoid therapy in hidradenitis suppurativa - a report of a case. Retinoids Today and Tomorrow 1990; 18: 28-30.
14. Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009; 218: 134-135.
15. Chow ET, Mortimer PS. Succesfull treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol 1992; 126: 415.
16. Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007; 33: 1340-1342. (Pubitemid 47624087)
17. Weyandt G. Operative Therapie der Acne Inversa. J Dtsch Dermatol Ges 2005; 56: 1033-1039.
18. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002; 359: 1542-1549. (Pubitemid 34621118)
19. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-326.
20. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002; 97: 2155-2156.
21. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroentereol 2003; 38: 1000-1014. (Pubitemid 37455790)
22. Lebwohl B, Sapadin A. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49: S275-S276.
23. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-1049.
24. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-1542. (Pubitemid 37523071)
25. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005; 16: 58-61. (Pubitemid 40283328)
26. Maalouf E, Faye O, Poli F, Cosnes A, Revuz J. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Venereol 2006; 133: 473-474.
27. Thielen Am, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 155: 1105-1107. (Pubitemid 44564546)
28. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-628. (Pubitemid 46400174)
29. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007; 32: 204-205. (Pubitemid 46233031)
30. Pedraz J, Daudén E, Pérez-Gala S, Goiriz-Valdés R, Fernández-Peñas P, Garcĩa-Diez A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr 2007; 98: 325-331.
31. Fernàndez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatololgy 2007; 215: 41-44.
32. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
33. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007; 46: 1287-1291.
34. Antonucci A, Negosanti M, Negosanti L, Iozzo I, Varotti C. Acne inversa treated with infliximab: different outcome in 2 patients. Acta Derm Venereol 2008; 88: 274-275. (Pubitemid 351743874)
35. Pedràz J, Penas PF, Garcia-Diez A. Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy. J Eur Acad Dermatol Venereol 2008; 22: 1500-1501
36. Elkjaer M, Dinesen L, Benazzato L, Rodriquez J, Løgager V, Munkholm P. Efficacy of infliximab treatment in patients with severe fistulizing hidradenitis suppurativa. J Crohn's Colitis 2008; 2: 241-245.
37. Montes-Romero JA, Callejas-Rubio JL, Sánchez-Cano D, González-Martínez FJ, Navas-Parejo A, Ortego-Centeno N. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab. Eur J Intern Med 2008; 19: 32-33.
38. Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, et al. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit 2009; 15: CS14-CS18.
39. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002; 27: 528-529.
40. Benìtez-Macìas JF, Garcia-Gil D, Brun-Romero FM. Fatal pneumococcal sepsis in patient with hidradenitis suppurativa treated with infliximab. Med Clin 2008; 131: 799.
41. Jurgensmeyer JC, Fleisher A. Clinical improvement of refractory hidradenitis suppurativa with etanercept. J Acad Dermatol 2004; 50; P15-P15.
42. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 17; 97-107.
43. Henderson RL Jr. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 2006; 5: 1010-1011.
44. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572.
45. Zangrilli A, Esposito M, Mio G, Mazzotta A, Chimenti S. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2008; 22; 1260-1262.
46. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-573
47. Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89: 82-83.
48. Arriola-Villalobos P, Díaz-Valle D, Alejandre-Alba N, López-Abad C, Méndez-Fernández R, Benítez-del- Castillo JM. Bilateral candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye 2008; 22: 5599-6000.
49. Ravat F, O'Reilly D, Handfield-Jones S. Recalcitrant hidradenitis suppurativa treated with adalimumab. J Am Acad Dermatol 2005; 52: P58.
50. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol 2006; 55: 163-164. (Pubitemid 43867032)
51. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-1112.
52. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19; 180-181.
53. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009; 8: 181-183.
54. Harde V, Mrowietz U. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges 2009; 7: 139-141.
55. Blanco R, Martinez-Taboada VM, Villa I, Gonzalez-Vela C, Fernandez-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009; 145: 580-584.
56. Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17; 455-472.
57. Gniadecki R, Jemec GB. Lipid raft/enriched stem cell/like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Dermatol 2004; 13: 361-363.
58. Streit M, Beleznay Z, Braathen LR. Topical application of the tumor necrosis factor/alpha antibody infliximab improved healing of chronic wounds. Int Wound J 2006; 3: 171-179. (Pubitemid 44426698)
59. Charles CA, Romanelli P, Martinez ZB, Ma F, Roberts B, Kirsner RS. Tumor necrosis factor/alpha in nonhealing venous leg ulcers. J Am Acad Dermatol 2009; 60: 951-955.
60. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213. (Pubitemid 36966545)
61. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009 [Epub ahead of print]. DOI: 10.1111/j.1365-2133.2009.09198.x
62. Matusiak Ł, Bieniek A, Szepietowski JC. Increased Serum Tumour Necrosis Factor-α in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor-α Agents? Acta Derm Venereol 2009; 89: 601-603.